Trials / Completed
CompletedNCT00327223
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- AmpliMed Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imexon |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-09-01
- Completion
- 2006-10-01
- First posted
- 2006-05-18
- Last updated
- 2008-03-14
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00327223. Inclusion in this directory is not an endorsement.